Diagnosing and treating depression in the medically ill;Diagnosticando e tratando depressão no paciente com doença clínica

Jornal Brasileiro de Psiquiatria

Volumn 55, Issue 1, 2006, Pages 8-19

  Furlanetto, Letícia Maria ^a,c   Brasil, Marco Antonio ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

BEHAVIOR; CLINICAL FEATURE; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; PREVALENCE;

EID: 33744940515     PISSN: 00472085     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0047-20852006000100002     Document Type: Conference Paper

References (121)

1. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke, 25:1099-104, 1994.
2. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand, 62: 210-9, 1980.
3. Appolinario JC, Bueno JR, Coutinho W. Psychotropic drugs in the treatment of obesity: what promise? CNS Drugs, 18: 629-51, 2004.
4. Arinzon ZH, Lehman YA, Fidelman ZG, Krasnyansky, II. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother, 36: 1175-7, 2002.
5. Blazer DG, Hughes D, George LK, Swartz M, Boyer R. Generalized anxiety disorder. In: Robins LN, Regier DA. Psychiatry disorders in America: the epidemiologic catchment area study. Free Press, p. 180-203, New York, 1993.
6. Block S, Kissane. Psychotherapies in psycho-oncology: an exciting new challenge. British Journal of Psychiatry, 177: 112-6, 2000.
7. Botega NJ, Bio MR, Zomignani MA, Garcia C, Jr., Pereira WA. Mood disorders among inpatients in ambulatory and validation of the anxiety and depression scale HAD. Rev Saude Publica, 29: 355-63, 1995.
8. Brasil MAA. Medicamentos. In: Fráguas Júnior R, Figueiredo JAB, editores. Depressões em medicina interna e outras condições. Depressões secundárias. Atheneu, p. 333-45, São Paulo, 2001.
9. Brasil MAA. Pacientes com queixas difusas: um estudo nosológico de pacientes com queixas multiplas e vagas. Tese de doutorado. Instituto de Psiquiatria da UFRJ, 1995.
10. Brasil MAA, Furlanetto LM. A atual nosologia psiquiátrica e sua adequação aos hospitals gerais. Cadernos do IPUB, Saúde mental no hospital geral, p. 59-70, 1997.
11. Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. Lancet, 356: 122-6, 2000.
12. Chochinov HM, Wilson KG, Enns M, Lander S. Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry, 151: 537-40, 1994.
13. Cigognini MA, Furlanetto LM. Treatment of depressive patients in a general hospital. Rev Bras Psiquiatr, 28 (no prelo), 2006.
14. Clarke DM, Kissane DW. Demoralization: its phenomenology and importance. Aust NZJ Psychiatry, 36: 733-42, 2002.
15. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med, 163: 59-64, 2003.
16. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med, 63: 619-30, 2001.
17. de Jonge P, Kempen GI, Sanderman R, et al. Depressive symptoms in elderly patients after a somatic illness event: prevalence, persistence and risk factors. Psychosomatics, 47: 33-42, 2006a.
18. de Jonge P, Spijkerman TA, van den Brink RH, Ormel J. Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months. Heart, 92: 32-9, 2006b.
19. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry, 37 Suppl 1: S39-45, 2004.
20. Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol Psychol, 57: 141-52, 2001.
21. Eisch AJ, Nestler EJ. To be or not to be: adult neurogenesis and psychiatry. Clin Neuroscience Res, 2: 93-108, 2002.
22. Endicott J. Measurement of depression in patients with cancer. Cancer, 53: 2243-9, 1984.
23. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry, 58: 175-89, 2005.
24. Everson SA, Kaplan GA, Goldberg DE, Salonen JT. Hypertension incidence is predicted by high levels of hopelessness in Finnish men. Hypertension, 35: 561-7, 2000.
25. Farrell KR, Ganzini L. Misdiagnosing delirium as depression in medically ill elderly patients. Arch Intern Med, 155: 2459-64, 1995.
26. Ferrando SJ, Rabkin JG, de Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry, 60: 741-6, 1999.
27. Figueiredo JM. Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry, 34: 308-11, 1993.
28. Figueiredo JM. Some issues in research on the epidemiology of demoralization. Compr Psychiatry, 24: 154-7, 1983.
29. Figueiredo, JM, Frank JD. Subjetive incompetence, the clinical hallmark of demoralization. Compr Psychiatry, 23: 353-63, 1982.
30. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med, 32: 305-16, 2000.
31. Fleck MAP, Soares HH. Estudo preliminar da prevalência de alcoolismo em pacientes internados no pronto-socorro de Porto Alegre. Rev Psiquiatr RS, 12: 84-7, 1990.
32. Fornari LM, Furlanetto LM. Freqüência de sintomas depressivos em pacientes com história de infarto agudo do miocárdio. J Bras Psiquiatr, 51: 385-90, 2002.
33. Fortes S. Transtornos mentais na atenção primária: suas formas de apresentação, perfil nosológico e fatores associados em unidades do Programa de Saúde da Família do município de Petrópolis, Rio de Janeiro, Brasil. 2004. Tese (doutorado). Universidade do Estado do Rio de Janeiro, Rio de Janeiro.
34. Fráguas Jr. R, Gonsalves Henriques Jr. S, De Lucia MS, et al. The detection of depression in medical setting: a study with PRIME-MD. J Affect Disord, 91: 11-7, 2006.
35. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA, 270: 1819-25, 1993.
36. Furlanetto LM. Diagnosticando depressão em pacientes internados em enfermarias de clínica médica. J Bras Psiq, 45: 363-70, 1996.
37. Furlanetto LM. Aspectos metodológicos da pesquisa em interconsulta psiquiátrica. J Bras Psiq, 46: 371-6, 1997a.
38. Furlanetto LM. Depressão mascarada existe? Rev Bras Med Psicossom, 1, 1997b.
39. Furlanetto LM. Diagnóstico. In: Fráguas Júnior R, Figueiredo JAB, editores. Depressões em medicina interna e em outras condições médicas. Depressões secundárias. Atheneu, p. 11-20, Rio de Janeiro, 2000.
40. Furlanetto LM, Bueno JR, Silva RV. Caracteristicas e evoluçã o de pacientes com transtornos depressivos durante a internação em enfermarias de clínica médica. J Bras Psiq, 47: 609-17, 1998.
41. Furlanetto LM, Mendlowicz MV, Romildo Bueno J. The validity of the Beck Depression Inventory - Short Form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients. J Affect Disord, 86: 87-91, 2005.
42. Furlanetto LM, von Ammon Cavanaugh S, Bueno JR, Creech SD, Powell LH. Association between depressive symptoms and mortality in medical inpatients. Psychosomatics, 41: 426-32, 2000.
43. Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy and functional recovery. J Neurol Neurosurg Psychiatry, 71: 258-61, 2001.
44. Gauer GJC, Furlanetto LM, Juruema MF, Vieira RM. Transtornos do humor. In: Neto AC, Gauer GJC, Furtado NR, editores. Psiquiatria para Estudantes de Medicina. Edipucrs, p. 386-406, Porto Alegre, 2003.
45. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA, 288: 701-9, 2002.
46. Goldberg DP, Huxley P. Common mental disorders: a bio-social model. Routledge, London, 1992.
47. Golden SH, Williams JE, Ford DE, et al. Depressive symptoms and the risk of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care, 27: 429-35, 2004.
48. Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr, 7: 547-60, 1995.
49. Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol, 60: 753-9, 2003.
50. Griffith JL, Gaby L. Brief psychotherapy at the bedside: countering demoralization from medical illness. Psychosomatics, 46(2): 109-16, 2005.
51. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol, 47: 246-9, 2000.
52. Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology, 7: 291-300, 1998.
53. House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke, 32: 696-701, 2001.
54. Jamison KR. The many stigmas of mental illness. Lancet, 367: 533-4, 2006.
55. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med, 352: 2515-23, 2005.
56. Koenig HG, George LK, Meador KG. Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. Am J Psychiatry, 154: 1369-75, 1997a.
57. Koenig HG, George LK, Peterson BL, Pieper CF. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry, 154: 1376-83, 1997b.
58. Kop WJ, Gottdiener JS. The role of immune system parameters in the relationship between depression and coronary artery disease. Psychosom Med, 67 Suppl 1: S37-41, 2005.
59. Kop WJ, Gottdiener JS, Tangen CM, et al. Inflammation and coagulation factors in persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol, 89: 419-24, 2002.
60. Kumar A, Thomas A, Lavretsky H, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry, 159: 630-6, 2002.
61. Kunik M, Braun U, Stanley M, et al. One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. Psychological Medicine, 31: 717-23, 2001.
62. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol, 4: 371-80, 2005.
63. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry, 42: 290-5, 1997.
64. Larson SL, Owens PL, Ford D, Eaton W. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke, 32: 1979-83, 2001.
65. Leibing E, Pfingsten M, Bartmann U, et al. Cognitive-behavioural treatment in unslected rheumatoid arthritis outpatients. Clin J Pain, 15: 58-66, 1999.
66. Leserman J, Petitto JM, Gu H, et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med, 32: 1059-73, 2002.
67. Lesperance F, Frasure-Smith N, Juneau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med, 160: 1354-60, 2000.
68. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med, 58: 99-110, 1996.
69. Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation, 105: 1049-53, 2002.
70. Lin EH, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care, 27: 2154-60, 2004.
71. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet, 1: 297-300, 1984.
72. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications, 19: 113-22, 2005.
73. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care, 23: 618-23, 2000.
74. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med, 59: 241-50, 1997.
75. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry, 60: 737-46, 2003.
76. Mangelli L, Fava GA, Grandi S, Grassi L, Ottolini F, Porcelli P, et al. Assessing demoralization and depression in the setting of medical disease. J Clin Psychiatry, 66(3): 391-4, 2005.
77. Manji H. Depression, III: treatments. Am J Psychiatry, 160: 24, 2003.
78. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol, 90: 1279-83, 2002.
79. Montano CB. Recognition and treatment of depression in a primary care setting. J Clin Psychiatry, 55 Suppl: 18-34; discussion 35-7, 1994.
80. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry, 62 Suppl 3: 10-21, 2001.
81. Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry, 6: 350-2, 2001.
82. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry, 54: 317-29, 2003.
83. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med, 344: 961-6, 2001.
84. Nobuhara K, Okugawa G, Sugimoto T, et al. Frontal white matter anisotropy and symptom severity of late-life depression: a magnetic resonance diffusion tensor imaging study. J Neurol Neurosurg Psychiatry, 77: 120-2, 2006.
85. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr, 13: 233-40, 2001.
86. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat, 70: 1-10, 2001.
87. Polsky D, Doshi JA, Marcus S, et al. Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med, 165: 1260-6, 2005.
88. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation, 94: 3123-9, 1996.
89. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry, 156: 101-7, 1999.
90. Rafanelli C, Roncuzzi R, Milaneschi Y, Tomba E, Colistro MC, Pancaldi LG, et al. Stressful life events, depression and demoralization as risk factors for acute coronary heart disease. Psychother Psychosom, 74(3): 179-84, 2005.
91. Roberts RE, Deleger S, Strawbridge WJ, Kaplan GA. Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes Relat Metab Disord, 27: 514-21, 2003.
92. Robinson RC, Rabins PV. Depression and coexisting disease. Igaku-Shoin, New York, 1989.
93. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry, 54: 376-87, 2003.
94. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry, 157: 351-9, 2000.
95. Rumsfeld JS, Jones PG, Whooley MA, et al. Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J, 150: 961-7, 2005.
96. Rodin G, Craven J, Littlefield C. Depression in the medically ill. Brunner&Mazel, New York, 1991.
97. Rundell JR, Wise MG. The American Psychiatric Press textbook of consultation-liaison psychiatry. American Psychiatric Press, Washington, 2005.
98. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry, 29: 201-17, 2005.
99. Schildkraut JJ, Klein FD. The classification and treatment of depressive states. In: Shader RI. Manual of Psychiatric Therapeutics. Little&Brown, Boston, 1975.
100. Shader RI. Demoralization revisited. J Clin Psychopharmacology, 25(4): 291-2, 2005.
101. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol, 46: 656-9, 2005.
102. Simen BB, Duman CH, Simen AA, Duman RS. TNF-alpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry, 2006.
103. Simon GE, Von Korff M. Medical co-morbidity and validity of DSM-IV depression criteria. Psychol Med, 36: 27-36, 2006.
104. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry, 54: 269-82, 2003.
105. Strain JJ. Psychiatric diagnostic dilemmas in the medical setting. Aust N Z J Psychiatry, 39: 764-71, 2005.
106. Sullivan MD, LaCroix AZ, Baum C, Grothaus LC, Katon WJ. Functional status in coronary artery disease: a one-year prospective study of the role of anxiety and depression. Am J Med, 103: 348-56, 1997.
107. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry, 62: 792-8, 2005.
108. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA, 277: 1618-23, 1997.
109. Villano LA, Nanhay ALG, Moraes LR, Costa e Silva JA. Results from the Rio de Janeiro Centre in Mental Illness in General Health Care: an International Study. In: Ustün TB, Sartorius N, editors. John Wiley & Sons Ltd, 1995.
110. von Ammon Cavanaugh S. Depression in the medically ill. Critical issues in diagnostic assessment. Psychosomatics, 36: 48-59, 1995.
111. von Ammon Cavanaugh S, Furlanetto LM, Creech SD, Powell LH. Medical illness, past depression and present depression: a predictive triad for in-hospital mortality. Am J Psychiatry, 158: 43-8, 2001.
112. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med, 17: 504-11, 2002.
113. Wells K, Sherbourne C, Duan N, et al. Quality improvement for depression in primary care: do patients with subthreshold depression benefit in the long run? Am J Psychiatry, 162: 1149-57, 2005.
114. White CA. Cognitive behavior therapy for chronic medical problems: a guide to assessment and treatment in practice. John Wiley, West Sussex, 2001.
115. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke, 31: 1829-32, 2000.
116. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry (no prelo), 2006.
117. Yasui-Furukori N, Kaneko S. Digitalis intoxication induced by paroxetine co-administration. Lancet, 367: 788, 2006.
118. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St. John's wort. J Psychopharmacol, 18: 262-76, 2004.
119. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med, 160: 1818-23, 2000.
120. Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA, 286(13): 1621-7, 2001.
121. Zubenko GS, Zubenko WN, McPherson S, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry, 160: 857-66, 2003.